Jeremy Tigue worked in the City for more than thirty years and was the fund manager of F&C Investment Trust until 2014. He is now a director of several other investment companies. Jeremy has a Modern History degree from Oxford University and is a graduate of the Advanced Management Program at the Harvard Business School.
Steve Bates is a director GuardCap Asset Management Ltd, an asset management company. He has had a long career as a portfolio manager originally with Flemings, then with JP Morgan and since 2003 with the predecessor business of GuardCap. He sits on a number of Boards as Chairman or non-executive director, including Biotech Growth Trust plc, a London listed investment trust specialising in the biotechnology industry. Steve has a law degree from Cambridge University and is a Chartered Financial Analyst.
Francesca joined us as a Trustee in May 2019. She is the Director of London Advanced Therapies, a programme that brings together the academic community in London working in the field of gene and cell therapies. Prior to this role, Francesca was the Director of Grants at the Bart's Charity for three years. Francesca has a Master's degree in Industrial Chemistry from Milano University and a PhD in Structural Biology from Padova University. Following a Postdoctural Research Fellowship in Groningen, the Netherlands, Francesca has worked at the pharma-academia interface, having held various positions in universities and commercial companies in the UK and overseas.
After reading physiology at the University of Sheffield Rod Flower began a postgraduate degree at the Royal College of Surgeons in London and was awarded his PhD in 1974. Rod then worked at the Wellcome Foundation for 12 years, leaving in 1985 to take up the Chair of Pharmacology at the University of Bath.
In 1989, Rod moved to Barts and the London Charterhouse Square where, together with Sir John Vane and others, he set up the William Harvey Research Institute. He remained there directing his department of Biochemical Pharmacology until his retirement in 2015. Rod was a Principal Fellow of the Wellcome Trust from 1994-2007 and was elected to fellowship of the Academy of Medical Sciences (1999) and the Royal Society (2003). He is now an Emeritus Professor of Pharmacology.
Kathryn is a Trustee and Chair, Audit & Risk Committee of the William Harvey Research Foundation. She is also a Non-executive Director and Chair, Audit and Risk Committee of Planet Smart City. She is a member of the Risk Coalition. Kathryn has more than 35 years’ experience in the financial sector, most recently at RBS, where she led a team responsible for reviewing customer complaints in relation to a strategic remediation project. Previously, she was Head of Enterprise Risk Reporting for the bank. She joined RBS from Moody’s Investors Service, where she held a number of analytical and managerial roles in the UK, the US and Singapore. Earlier in her career, she founded and managed The Paradigm Alliance, a consulting firm based in Sydney, Australia. She began her career in finance at The Chase Manhattan Bank. Kathryn served as a Peace Corps Volunteer in Fez, Morocco. Kathryn holds a BA from Bryn Mawr College and an MA from Georgetown University, both of the US.
Professor Caulfield is Professor of Clinical Pharmacology at Queen Mary University of London and the Vice Principal for Health for Queen Mary’s Faculty of Medicine and Dentistry. He graduated in Medicine in 1984 from the London Hospital Medical College and trained in Clinical Pharmacology at St Bartholomew’s Hospital where he developed a research programme in molecular genetics of hypertension and translational clinical research.
Professor Caulfield was Director of Queen Mary’s William Harvey Research Institute between 2002-2020 and was elected to the Academy of Medical Sciences in 2008. He has won the Lily Prize of the British Pharmacology Society, the Bjorn Folkow Award of the European Society of Hypertension 2016 and the Franz Volhard Award of the International Society of Hypertension in 2018.
Professor Caulfield is a member of the Barts Health NHS Trust Board, the Barking, Havering and Redbridge University Hospitals NHS Trust, the MedCity Board and is the President Elect of the British Pharmacological Society.
Andy worked for over 25 years in the Retail and Leisure sector as Finance Director covering PLCs, AIM listed businesses and private companies, both family owned and private equity backed. He qualified as a chartered accountant with Price Waterhouse and completed an MBA whilst working at Whitbread plc. Andy has undertaken other charity Trustee and company Non exec roles and since retirement has spent more time playing tennis and travelling the world.
Vanela Bushi is an experienced investor and industry executive with over 16 years in the biopharma and healthcare sectors. She is currently co-founder and GP at H Tree Capital, a specialist venture fund focusing on deep tech and with particular focus on opportunities at the intersection of tech and life sciences and healthcare more broadly. Prior to H Tree Capital, she held senior positions with the London offices of Syneos Health, EY Parthenon and PwC focusing on transactions in the biopharma space. Early in her career, Vanela held roles with the Investments Teams at the Wellcome Trust and IP Group (formerly Touchstone Innovations). She holds degrees from McGill University in Canada and Imperial College London.
Clive Page is Professor of Pharmacology, King’s College London. Clive’s main research interests are in the pharmacology of inflammation and respiratory disease, and he has published over 300 scientific papers and book chapters.
Clive was the co-founder and previous Chairman of the Board of Verona Pharma plc, a NASDAQ listed Company developing new drugs for the treatment of Respiratory Diseases. He is a Trustee of the Fraunhofer Institute of Toxicology and Experimental Medicine in Hannover. Clive is also a Non Executive Director of Ananda Developments. Clive started his early career in the Pharmaceutical Industry at Sandoz Ltd, Basel, Switzerland and regularly consults to both Pharmaceutical and Biotech companies. Clive has previously held Non Executive Board positions at Cardiome in Canada, Stirling Products Ltd in Perth, Australia, Immune Regulation Ltd, Epiendo, PreP Biopharma, Babraham Biotechnology Ltd and as a Trustee of the Babraham Institute, Cambridge.
Clive is a former Chairman of the Animal Science Group of the Royal Society of Biology and has contributed widely to the public debate about the use of animals in Research. Clive is a recent past President of the British Pharmacological Society.
Clive was awarded the Sandoz Prize from the British Pharmacological Society in 1988, The Tanabe Young Investigators Prize from the American College of Clinical Pharmacology in 1996 and the Society of Biology President’s Medal in 2012 for “Outstanding Contributions to the Life Sciences”. He is a Fellow of the Royal Society of Biology and an Honorary Fellow of the British Pharmacological Society and the Faculty of Pharmaceutical Medicine, Royal College of Physicians. Clive was awarded an OBE for “Services to Pharmacology” in 2017.
Stephen DeCherney is Professor of Medicine in the Kenan-Flagler School of Business, University of North Carolina (UNC). Prior to joining the faculty at UNC, Stephen worked at Quintiles Transnational Corporation. Stephen is also a Director of Health Decisions, Inc. and a Senior Advisor to Anagenesis Capital Partners, Inc. He also serves as Chair of the University of Delaware Research Foundation. He is a Trustee of the Christiana Care Health System, Delaware.
Stephen graduated from Columbia College, Columbia University in New York City where he received a BA in Biology and was awarded the Columbia College Alumni Achievement Award granted to the “Senior Adjudged Most Outstanding in Qualities of Mind, Character, and Service to the College”. He received his medical degree from Temple University in Philadelphia, and earned an MPH, Healthcare Management, from Columbia University School of Public Health. Stephen is author or co-author of over 100 publications.
